Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29467517 | 0.85 | ALDH1A1 (0.37) | EGFR | |
| SCHEMBL21631800 | 0.85 | ALDH1A1 (0.37) | EGFR | |
| SCHEMBL14905211 | 0.81 | EGFR (0.38) | EGFRMELK | |
| SCHEMBL14905348 | 0.78 | EGFR (0.41) | EGFR | |
| SCHEMBL21494203 | 0.77 | EGFR (0.33) | EGFRMELK | |
| SCHEMBL14978386 | 0.77 | ALDH1A1 (0.41) | EGFRMELK | |
| SCHEMBL31745274 | 0.74 | EGFR (0.40) | EGFR | |
| SCHEMBL21631593 | 0.74 | NQO2 (0.33) | — | |
| SCHEMBL24569769 | 0.73 | CSNK1A1 (0.40) | EGFR | |
| SCHEMBL16804755 | 0.73 | MELK (0.36) | EGFRMELK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-9757364-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2017-09-12 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170105978-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-20 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-9527844-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2016-12-27 | — | — | US | disclosed |
| US-20160108034-A1 | NAPHTHYRIDINE DERIVATIVE COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-9309241-B2 | Naphthyridine derivative compounds | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20150057293-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| WO-2013061077-A1 | NEW COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057293-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | EGFR 1182/4885MELK 3404/4885 |
| US-20170105978-A1 | NEW COMPOUNDS | NQO1, NTPCR, NDC1 | EGFR 1182/4885MELK 3404/4885 |
| US-20160108034-A1 | NAPHTHYRIDINE DERIVATIVE COMPOUNDS | NQO1, NDC1, NTPCR | EGFR 1282/4885MELK 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.